Patents by Inventor Jack A. Roth

Jack A. Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6805858
    Abstract: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
    Type: Grant
    Filed: October 6, 1999
    Date of Patent: October 19, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Wei-Wei Zhang, Jack A. Roth
  • Patent number: 6797702
    Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: September 28, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
  • Patent number: 6740320
    Abstract: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 25, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Wei-Wei Zhang, Jack A. Roth
  • Publication number: 20040028654
    Abstract: Embodiments of the invention include methods and compositions including viral composition that have high transduction efficiencies in vivo, in vitro and ex vivo. The viral composition include a viral vector and a protamine molecule, wherein the viral vector includes a polynucleotide encoding a tumor suppressor gene. The methods of the invention include administering the viral composition to a patient or subject for treatment of disease, in particular cancer, that is characterized by a reduced vector-induced production of neutralizing antibodies and a decreased vector-induced toxicity as compared to delivery of viral vectors alone.
    Type: Application
    Filed: March 24, 2003
    Publication date: February 12, 2004
    Applicant: Board of Regents, The University of Texas System
    Inventors: Lin Ji, Jack Roth
  • Publication number: 20040016006
    Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
    Type: Application
    Filed: May 27, 2003
    Publication date: January 22, 2004
    Applicant: U.S. of America, represented by the Secretary, Department of Health and Human Services.
    Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
  • Publication number: 20040009939
    Abstract: The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.
    Type: Application
    Filed: March 3, 2003
    Publication date: January 15, 2004
    Applicants: Board of Regent, The University of Texas System, Introgen Therapeutics, Inc.
    Inventors: Sunil Chada, Abujiang Pataer, Abner Mhashilkar, Rajagopal Ramesh, Jack Roth, Steve Swisher
  • Patent number: 6630344
    Abstract: The present invention provides viral vectors that have been engineered to contain a synthetic promoter that controls at least one essential gene. The synthetic promoter is induced by a specific gene product not normally produced in the cells in which the viral vector is to be transferred. The vectors are propagated in producer or helper cells that express the inducing factor, thereby permitting the virus to replicate to high titer. The lack of the inducing factor in the target cells precludes viral replication, however, meaning that no vector toxicity or immunogenicity arises. Where the virus carries a gene of interest, this should provide for higher level expression for longer periods of time than with current vectors. Methods for making the vectors, helper cells, and their use in protein production, vaccines and gene therapy are disclosed.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: October 7, 2003
    Assignee: Texas Systems, University of the Board of Regents
    Inventors: Bingliang Fang, Jack A. Roth
  • Patent number: 6627189
    Abstract: Disclosed are methods and compositions for the selective inhibition gene expression through the application of antisense RNA technology. Antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: September 30, 2003
    Assignee: Board of Regents, The University of Texas Systems
    Inventors: Jack A. Roth, Tapas Mukopadhyay, Michael Tainsky
  • Publication number: 20030099614
    Abstract: The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with methoxyestradiol. 2-methoxyestradiol (2-MeOE2) increase wild-type p53 levels in a human non-small lung cancer cell lines associated with accumulation of cyclin dependent kinase inhibitor p21WAF1/CIP1. Significant apoptotic cell death occurred after the drug treatment. Thus, 2-MeOE2 facilitates induction of p53-mediated apoptosis.
    Type: Application
    Filed: June 25, 2002
    Publication date: May 29, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: Tapas Mukhopadhyay, Jack A. Roth
  • Publication number: 20030083303
    Abstract: An adenoviral supervector system is disclosed that is capable of expressing more than 7.5 kilobases of heterologous DNA in a replication defective adenoviral vector. The supervector system comprises an adenoviral vector construct and a helper cell. The vector construct is capable of being replicated and packaged into a virion particle in the helper cell. In particular, the helper cell expresses DNA from the E2 region of the adenovirus 5 genome and complements deletions in that region in the vector construct.
    Type: Application
    Filed: September 19, 2002
    Publication date: May 1, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: Wei-Wei Zhang, Jack Roth
  • Publication number: 20030039631
    Abstract: Disclosed are methods and compositions for the selective manipulation of gene expression through the preparation of retroviral expression vectors for expressing antisense sequences, such as K-ras oncogene antisense sequences, or sequences encoding a desired product, such as wild type p53 sequences. Preferred retroviral vectors of the present invention incorporate the &bgr;-actin promoter in a reverse orientation with respect to retroviral transcription. Preferred antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged.
    Type: Application
    Filed: November 23, 1999
    Publication date: February 27, 2003
    Inventor: JACK A. ROTH
  • Publication number: 20030021767
    Abstract: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
    Type: Application
    Filed: June 25, 2002
    Publication date: January 30, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: Wei-Wei Zhang, Jack A. Roth
  • Patent number: 6511847
    Abstract: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: January 28, 2003
    Assignee: Board of Regents, The University of Texas System
    Inventors: Wei-Wei Zhang, Jack A Roth
  • Publication number: 20030012770
    Abstract: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
    Type: Application
    Filed: June 11, 2002
    Publication date: January 16, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: Wei-Wei Zhang, Jack A. Roth
  • Patent number: 6482803
    Abstract: The present invention discloses expression constructs and methods for employing them that result in the modulation of abnormal oncogene and tumor suppressor genes in a novel approach to cancer prevention and therapy. In one embodiment, an expression construct expresses a ribozyme that inactivates mutant p53 and also expresses the functional p53.
    Type: Grant
    Filed: September 1, 1995
    Date of Patent: November 19, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack A. Roth, De Wei Cai, Tapas Mukhopadhyay
  • Publication number: 20020164715
    Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
    Type: Application
    Filed: July 10, 2001
    Publication date: November 7, 2002
    Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
  • Patent number: 6436700
    Abstract: Disclosed are methods and compositions for the selective inhibition gene expression through the application of antisense RNA technology. Antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: August 20, 2002
    Assignee: Board of Regents, The University of Texas Systems
    Inventors: Jack A. Roth, Tapas Mukopadhyay, Michael Tainsky
  • Patent number: 6410029
    Abstract: The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with methoxyestradiol. 2-methoxyestradiol (2-MeOE2) increase wild-type p53 levels in a human non-small lung cancer cell lines associated with accumulation of cyclin dependent kinase inhibitor p21 WAF1/CIP1. Significant apoptotic cell death occurred after the drug treatment. Thus, 2-MeOE2 facilitates induction of p53-mediated apoptosis.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: June 25, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Tapas Mukhopadhyay, Jack A. Roth
  • Patent number: 6410010
    Abstract: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.
    Type: Grant
    Filed: October 29, 1993
    Date of Patent: June 25, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Wei-Wei Zhang, Jack A Roth
  • Patent number: 6251871
    Abstract: A variety of genetic constructs are disclosed that will find both in vitro and in vivo use in the area of tumor biology and cancer therapy. In particular, expression constructs are provided that contain a p16 encoding region and other regulatory elements necessary for the expression of a p16 transcript. One version of the expression construct is a replication-deficient adenoviral vector. Also provided are methods for the transformation of cell lines and the inhibition of cancer cell proliferation.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: June 26, 2001
    Assignee: Board of Regents, The University of Texas System
    Inventors: Xiaomei Jin, Jack A. Roth